3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
OTHER
2
NETWORK
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
45
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Leukemia
19
Lymphoma
15
Burkitt Lymphoma
8
Neoplasms, Plasma Cell
5
Hodgkin Disease
5
Recurrence
4
Leukemia, Biphenotypic, Acute
4
Immunoglobulin Light-chain Amyloidosis
4
Waldenstrom Macroglobulinemia
3
Lymphoma, Large B-Cell, Diffuse
3
Lung Neoplasms
3
Vomiting
2
Prostatic Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Nausea
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Disease
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Smoldering Multiple Myeloma
1
Seminoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Interventions
Cyclophosphamide
3
carfilzomib
2
Dexamethasone
2
deltacortene
1
daratumumab
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Calcium Dobesilate
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
NETWORK
×
Disease
×
Dexamethasone
×
Clear all
NCT01857115
2024-11-13
wCCyd
European Myeloma Network B.V.
Phase 1/2
Completed
63 enrolled
NCT02204241
2023-07-03
CCD
European Myeloma Network B.V.
Phase 1/2
Completed
36 enrolled